Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
217.71B
Market cap217.71B
Price-Earnings ratio
13.36
Price-Earnings ratio13.36
Dividend yield
2.68%
Dividend yield2.68%
Average volume
21.86M
Average volume21.86M
High today
$49.43
High today$49.43
Low today
$46.53
Low today$46.53
Open price
$47.07
Open price$47.07
Volume
27.22M
Volume27.22M
52 Week high
$112.52
52 Week high$112.52
52 Week low
$45.05
52 Week low$45.05

Stock Snapshot

With a market cap of 217.71B, Novo Nordisk(NVO) trades at $49.30. The stock has a price-to-earnings ratio of 13.36 and currently yields dividends of 2.7%.

On 2025-11-11, Novo Nordisk(NVO) stock moved within a range of $46.53 to $49.43. With shares now at $49.30, the stock is trading +6.0% above its intraday low and -0.3% below the session's peak.

Trading activity shows a volume of 27.22M, compared to an average daily volume of 21.86M.

Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $45.05.

Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $45.05.

NVO News

24/7 Wall St. 6h
TSMC, Fastenal And Novo Nordisk Offer Fast Dividend Growth For Long-Term Investors

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts Quick Read TSMC (TSM) manufactures chips for Nvidia and AMD and holds major pricing power over the te...

TSMC, Fastenal And Novo Nordisk Offer Fast Dividend Growth For Long-Term Investors
TipRanks 7h
Prothena highlights positive Phase 2 Coramitug data published in AHA journal

Prothena (PRTA) announced the publication of Phase 2 clinical trial data for coramitug for the treatment of ATTR amyloidosis with cardiomyopathy in the American...

The Motley Fool 12h
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?

Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs. The market for GLP-1 drugs is already white-hot a...

Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?

Analyst ratings

61%

of 33 ratings
Buy
60.6%
Hold
33.3%
Sell
6.1%

More NVO News

The Wall Street Journal 1d
What’s Next for Novo Nordisk?

After losing out to Pfizer for a weight-loss drug startup, Novo Nordisk will now have to count more heavily on its own research labs for new drugs, even as it’s...

What’s Next for Novo Nordisk?
TipRanks 1d
Novo Nordisk price target lowered to DKK 315 from DKK 375 at BofA

BofA lowered the firm’s price target on Novo Nordisk (NVO) to DKK 315 from DKK 375 and keeps a Neutral rating on the shares. The firm, which assumes a reported...

Investor's Business Daily 1d
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion

Metsera (MTSR) stock toppled Monday after the buyout battle with Pfizer (PFE) and Novo Nordisk (NVO) ended. Pfizer will acquire the small obesity-focused biotec...

Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion
MarketWatch 1d
Metsera shares drop on deal news, and other early morning movers

Here are some of the stocks making notable moves in Monday's premarket action: TreeHouse Foods shares are surging 19% after the food and beverage company agree...

Metsera shares drop on deal news, and other early morning movers
TipRanks 1d
Novo Nordisk Stock Rises on Plan to Pursue Other Obesity Deals after Metsera Loss

Danish drug giant Novo Nordisk’s shares rose modestly during early trading on Monday. This came after reports that Novo Nordisk’s pursuit of obesity market deal...

The Wall Street Journal 1d
Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle

Tom Ittle/Reuters Novo Nordisk NOVO.B 2.59 %increase; green up pointing triangle shares rose Monday after the Danish drugmaker withdrew from a bidding war with...

Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle
TipRanks 2d
Novo continues to look for opportunities in obesity, diabetes, Bloomberg says

While Novo Nordisk (NVO) may have lost Metsera (MTSR) to Pfizer (PFE), CEO Mike Doustdar doesn’t plan to give up on dealmaking any time soon, Eric Pfanner, Aaro...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.